Analytical procedure for the determination of the new antitumour drug N-benzoylstaurosporine and three potential metabolites in human plasma by reversed-phase high-performance liquid chromatography

R. van Gijn(Slotervaartziekenhuis), Jos H. Beijnen(The Netherlands Cancer Institute), Olaf van Tellingen(Dutch Cancer Society), J. J. M. de Clippeleir(Slotervaartziekenhuis), Epie Boven(Amsterdam University Medical Centers), W.W. ten Bokkel Huinink, J. B. Vermorken, M. J. X. Hillebrand(The Netherlands Cancer Institute), Peter Gräf(Heinrich Heine University Düsseldorf), S. Schwertz(Novartis (Switzerland))
Journal of Chromatography B Biomedical Sciences and Applications
May 1, 1995
10.1016/0378-4347(95)00037-j
Cited by 15

Related Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
|PubMed|2002|688